J 2021

Manganese and copper levels in patients with primary biliary cirrhosis and primary sclerosing cholangitis

DASTYCH, Milan, Libuse HUSOVA, Kvetoslava AIGLOVA, Tomas FEJFAR, Milan DASTYCH et. al.

Basic information

Original name

Manganese and copper levels in patients with primary biliary cirrhosis and primary sclerosing cholangitis

Authors

DASTYCH, Milan (203 Czech Republic, guarantor), Libuse HUSOVA (203 Czech Republic), Kvetoslava AIGLOVA (203 Czech Republic), Tomas FEJFAR (203 Czech Republic) and Milan DASTYCH (203 Czech Republic, belonging to the institution)

Edition

SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, ABINGDON, INFORMA HEALTHCARE, 2021, 0036-5513

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30219 Gastroenterology and hepatology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.209

RIV identification code

RIV/00216224:14110/21:00121702

Organization unit

Faculty of Medicine

DOI

UT WoS

000607121500001

Keywords in English

Manganese; copper; cholestasis; primary biliary cirrhosis; primary sclerosing cholangitis

Tags

Tags

International impact, Reviewed
Změněno: 3/6/2021 08:06, Mgr. Tereza Miškechová

Abstract

V originále

The liver and the biliary tree form the main excretory route of manganese (Mn) and copper (Cu). Cholestasis, can lead to the accumulation of these trace elements in the organism, resulting in toxicity to the basal ganglia of the central nervous system. The aim of our study was to reveal the influence of long-term cholestasis on the Mn and Cu levels in the blood of patients with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). We recruited patients with PBC (n = 20) and PSC (n = 32). A control group (n = 40) was also set up. We also examined serum bile acid concentrations and liver enzyme activities. We did not observe any significant differences in any of these parameters between the PBC and PSC groups. The Mn and Cu levels in the PBC and PSC patients differed significantly from the that in the control group (p < 0.0001 and p < .021, respectively). Patients in whom the laboratory cholestasis markers normalized during ursodeoxycholic acid treatment (18/52;35%) presented with significantly lower levels of Mn and Cu (p = .015 and p = .012, respectively). Ten PSC patients showed normal levels of Mn and Cu six months after liver transplantation. Fine tremors, rigidity, dysarthria, and hypomimia were reported in nine (23%), eight (20%), four (10%), and eight (20%) patients, respectively. In addition to monitoring the cholestasis levels, liver function, and Mn and Cu levels during the long-term treatment of PBC and PSC patients, it is important to also regularly monitor the occurrence and development of extrapyramidal symptoms of Parkinson's-like syndromes.